# Renal Function Improvement in HBsAg Positive Kidney Transplantation Patients Under Telbivudine Treatment.

> **NCT02894554** · PHASE4 · TERMINATED · sponsor: **National Taiwan University Hospital** · enrollment: 19 (actual)

## Conditions studied

- HBsAg-positive Renal Allograft Recipients

## Interventions

- **DRUG:** Telbivudine
- **DRUG:** Lamivudine

## Key facts

- **NCT ID:** NCT02894554
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07
- **Primary completion:** 2014-10
- **Final completion:** 2015-07
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** clinical myalgia
- **Last updated:** 2016-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02894554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02894554, "Renal Function Improvement in HBsAg Positive Kidney Transplantation Patients Under Telbivudine Treatment.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02894554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*